The three most talked-about weight loss injections compared head-to-head — efficacy, cost, side effects, and who each one is right for
Wegovy, Ozempic, and Mounjaro dominate the conversation around weight loss injections — but the relationship between them confuses most people. Two of them contain the same active ingredient. One works through a completely different mechanism. All three are frequently discussed interchangeably despite meaningful differences.
Here’s the complete, honest comparison.
Understanding What Each Medication Actually Is
Before comparing them — understanding what each medication is clarifies why the comparison is more nuanced than it appears.
Ozempic (Semaglutide)
Active ingredient: Semaglutide FDA approval: Type 2 diabetes management (2017) Weight loss use: Off-label — not FDA-approved for weight loss at Ozempic doses Dosing: Once weekly injection — available in 0.5mg, 1mg, and 2mg doses Manufacturer: Novo Nordisk
Ozempic was developed and approved for blood sugar management in type 2 diabetes. Its dramatic weight loss effect was initially a secondary finding — and became the primary reason millions of people without diabetes sought prescriptions for it.
Wegovy (Semaglutide)
Active ingredient: Semaglutide — the same molecule as Ozempic FDA approval: Chronic weight management (2021) Dosing: Once weekly injection — doses up to 2.4mg (higher than Ozempic’s maximum 2mg) Manufacturer: Novo Nordisk
Wegovy is essentially Ozempic at a higher dose, specifically developed and approved for weight loss. The key difference: Wegovy reaches 2.4mg — the dose shown to produce maximum weight loss in clinical trials. Ozempic tops out at 2mg.
The relationship between them: Same drug, different doses, different approved indications. Someone taking Ozempic 2mg off-label for weight loss is taking the same molecule as Wegovy 2mg — but can’t access the 2.4mg maintenance dose that Wegovy provides.
Mounjaro (Tirzepatide)
Active ingredient: Tirzepatide FDA approval: Type 2 diabetes management (2022) — weight loss approved as Zepbound (2023) Dosing: Once weekly injection — available in 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg doses Manufacturer: Eli Lilly
Mounjaro is a fundamentally different medication from Ozempic and Wegovy. While semaglutide is a GLP-1 receptor agonist (activating one hormonal pathway), tirzepatide is a dual GIP/GLP-1 receptor agonist — activating two complementary pathways simultaneously.
Zepbound is the same tirzepatide as Mounjaro, FDA-approved specifically for weight loss — the same relationship as Ozempic/Wegovy.
Head-to-Head Efficacy Comparison
This is the most important comparison — and the results are clear.
Clinical Trial Weight Loss Data
Wegovy (semaglutide 2.4mg) — STEP 1 Trial:
- Duration: 68 weeks
- Average weight loss: 14.9% of body weight
- Participants losing >10%: 69%
- Participants losing >20%: 32%
Ozempic (semaglutide 1mg, used off-label for weight loss) — SUSTAIN trials:
- Average weight loss: 4-6% of body weight
- Note: At 2mg, approximately 6-9% weight loss
Mounjaro/Zepbound (tirzepatide 15mg) — SURMOUNT-1 Trial:
- Duration: 72 weeks
- Average weight loss: 20.9% of body weight
- Participants losing >10%: 91%
- Participants losing >15%: 83%
- Participants losing >20%: 57%
The Direct Head-to-Head: Tirzepatide vs. Semaglutide (SURMOUNT-5)
The most definitive comparison — tirzepatide vs. semaglutide head-to-head in the same trial:
- Tirzepatide (10-15mg): 20.2% weight loss
- Semaglutide (2.4mg): 13.7% weight loss
- Difference: 6.5 percentage points in favor of tirzepatide
For a 200-pound person:
- Wegovy: approximately 27 lbs lost
- Mounjaro/Zepbound: approximately 40 lbs lost
The verdict on efficacy: Tirzepatide (Mounjaro/Zepbound) produces significantly greater weight loss than semaglutide (Wegovy/Ozempic) — at every dose comparison. This is one of the clearest head-to-head medication comparisons in recent clinical trial history.
Why Tirzepatide Outperforms Semaglutide
Understanding the mechanism explains the efficacy difference:
Semaglutide activates GLP-1 receptors — producing appetite suppression, slowed gastric emptying, and improved insulin signaling.
Tirzepatide activates both GLP-1 AND GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. GIP has complementary and additive effects:
- Direct effects on fat cell metabolism (increased fat breakdown)
- Complementary insulin signaling effects
- Possible buffering of some GLP-1 GI side effects
- Additional satiety signaling through independent pathways
The dual mechanism doesn’t just add the effects of each pathway — it appears to produce synergistic effects that result in greater total weight loss than either pathway alone would predict.
Side Effect Comparison
GI Side Effects (Nausea, Vomiting, Diarrhea)
Both medications cause GI side effects — but the comparison favors tirzepatide:
| Side Effect | Wegovy (Semaglutide) | Mounjaro (Tirzepatide) |
|---|---|---|
| Nausea | 44% | 31% |
| Vomiting | 24% | 12% |
| Diarrhea | 30% | 23% |
| Constipation | 24% | 17% |
Despite producing greater weight loss, tirzepatide causes significantly fewer GI side effects than semaglutide. This counterintuitive finding is likely related to GIP receptor activation moderating some of the GI effects of pure GLP-1 activation.
Practical implication: People who struggled with nausea on semaglutide sometimes tolerate tirzepatide better — a meaningful consideration for those who couldn’t complete semaglutide dose escalation.
Other Side Effects
Both medications share similar profiles for non-GI side effects:
- Hair loss (telogen effluvium) — both
- Gallbladder disease — both
- Injection site reactions — both
- Muscle loss risk without adequate protein/exercise — both
- Thyroid cancer warning — both (same black box warning)
As covered in our comprehensive guide to weight loss injection side effects, the management strategies are the same regardless of which medication is prescribed.
Cost Comparison
| Medication | Monthly Cost (No Insurance) | Notes |
|---|---|---|
| Wegovy (brand) | $1,300-1,500 | FDA-approved for weight loss |
| Ozempic (brand) | $900-1,000 | Off-label for weight loss |
| Mounjaro (brand) | $900-1,100 | Off-label for weight loss |
| Zepbound (brand) | $1,000-1,300 | FDA-approved for weight loss |
| Compounded semaglutide | $150-350 | Via telehealth providers |
| Compounded tirzepatide | $200-500 | Via telehealth providers |
As covered in our complete guide to how much weight loss injections cost, compounded versions through telehealth providers like Gala make both medications significantly more affordable than brand name retail pricing.
Cost verdict: At brand name prices, Ozempic and Mounjaro are modestly cheaper than their weight-loss-approved counterparts (Wegovy and Zepbound). Through compounded telehealth options, costs are similar. Brand name pricing differences are largely irrelevant for most people accessing through telehealth + compounding.
Insurance Coverage Comparison
Ozempic and Mounjaro (diabetes indication):
- Better insurance coverage — most plans covering diabetes medications include these
- Lower prior authorization burden for people with type 2 diabetes
- Medicare Part D covers for diabetes indication
Wegovy and Zepbound (weight loss indication):
- Coverage varies dramatically — many plans don’t cover weight loss medications
- Prior authorization almost always required
- Medicare Part D currently does not cover weight loss medications
- Manufacturer savings cards available for commercially insured patients
Practical implication: People with type 2 diabetes often access semaglutide or tirzepatide through their diabetes prescription (Ozempic/Mounjaro) at significantly lower cost than the weight-loss-approved versions. People without diabetes face more challenging insurance situations.
Approval Status Comparison
| Medication | Weight Loss Approval | Diabetes Approval |
|---|---|---|
| Ozempic | ❌ Off-label only | ✅ FDA-approved |
| Wegovy | ✅ FDA-approved | ❌ Not indicated |
| Mounjaro | ❌ Off-label only | ✅ FDA-approved |
| Zepbound | ✅ FDA-approved | ❌ Not indicated |
What “off-label” means in practice: Off-label prescribing is legal and extremely common — prescribers can prescribe any approved medication for any condition they believe it will benefit. Millions of people use Ozempic and Mounjaro off-label for weight loss with the full knowledge and support of their prescribers.
The approval distinction primarily affects insurance coverage and marketing — not whether the medication can be prescribed.
Cardiovascular Outcomes Comparison
Semaglutide (SELECT Trial):
- 17,604 participants with obesity and cardiovascular disease
- Semaglutide reduced major cardiovascular events (heart attack, stroke, CV death) by 20%
- Reduced all-cause mortality by 19%
Tirzepatide cardiovascular outcomes:
- The SURPASS-CVOT trial is ongoing — full cardiovascular outcomes data not yet available
- Earlier metabolic data strongly suggests cardiovascular benefit
- The greater weight loss and metabolic improvement with tirzepatide suggests potentially comparable or greater cardiovascular benefit
Current verdict: Semaglutide has the stronger cardiovascular outcomes evidence — the SELECT trial is landmark data. Tirzepatide’s cardiovascular outcomes trial will likely show similar or greater benefit but the definitive data isn’t yet published.
For people with established cardiovascular disease, semaglutide’s documented cardiovascular protection is a meaningful clinical consideration.
Head-to-Head: Which One Is Right for You?
Choose Wegovy/Ozempic (Semaglutide) if:
You have established cardiovascular disease: The SELECT trial’s documented 20% reduction in major cardiovascular events is specific to semaglutide — the strongest cardiovascular outcomes evidence currently available for any weight loss medication.
You’ve had poor GI tolerance previously: While both cause GI side effects, semaglutide’s profile is well-characterized — if you’ve previously managed semaglutide side effects adequately, switching to tirzepatide for greater efficacy is an option, but starting with the well-understood option has merit.
Cost or access factors: In some situations, compounded semaglutide is more readily available or slightly cheaper than compounded tirzepatide.
You have type 2 diabetes with Ozempic coverage: If your insurance covers Ozempic for diabetes, starting there before considering switching to tirzepatide may be the most cost-effective approach.
Choose Mounjaro/Zepbound (Tirzepatide) if:
Maximum weight loss is the priority: The evidence is clear — tirzepatide produces approximately 6 percentage points more weight loss than semaglutide. For someone with significant obesity, this difference represents an additional 10-15 lbs.
You’ve tried semaglutide without adequate response: Non-response or partial response to semaglutide is a common reason to switch — tirzepatide’s different (dual) mechanism sometimes works for people who didn’t respond well to semaglutide.
GI side effects were intolerable on semaglutide: Counterintuitively, tirzepatide produces fewer GI side effects than semaglutide despite greater efficacy — people who couldn’t tolerate semaglutide’s nausea sometimes do better on tirzepatide.
You have type 2 diabetes: Tirzepatide produces greater HbA1c reduction than semaglutide — for people managing both diabetes and weight, tirzepatide addresses both more effectively.
You have sleep apnea: Zepbound has received specific FDA approval for obstructive sleep apnea alongside obesity — with compelling trial data showing dramatic sleep apnea improvement.
What About Ozempic Specifically?
Ozempic occupies an interesting position — it’s the same drug as Wegovy but at lower doses, with better insurance coverage for people with diabetes.
Ozempic makes sense if:
- You have type 2 diabetes and your insurance covers Ozempic
- You’re using it as a starting point before potentially transitioning to Wegovy at weight loss doses
- Cost and insurance navigation favor the diabetes indication
Ozempic is less ideal than Wegovy if:
- Maximum weight loss is the goal — Wegovy reaches 2.4mg while Ozempic tops at 2mg
- You don’t have type 2 diabetes — the insurance coverage advantage disappears
The Practical Decision Framework
Step 1: Do you have type 2 diabetes?
- Yes → Ozempic or Mounjaro likely covered by insurance. Start there.
- No → Wegovy, Zepbound, or compounded versions are the pathway.
Step 2: What’s your primary goal?
- Maximum weight loss → Tirzepatide (Mounjaro/Zepbound)
- Cardiovascular protection with weight loss → Semaglutide (Wegovy) has more evidence
- Both → Tirzepatide likely still wins on balance
Step 3: What’s your access and cost situation?
- Good insurance covering weight loss medications → Brand name, either medication
- No insurance or poor coverage → Telehealth + compounded, cost similar for both
- Manufacturer savings card eligible → Check both Novo Nordisk and Eli Lilly programs
Step 4: Have you tried one before?
- Tried semaglutide, inadequate response → Switch to tirzepatide
- Tried semaglutide, intolerable GI effects → Try tirzepatide (fewer GI side effects)
- New to both → Tirzepatide if maximum efficacy is priority
How to Get Started
Medical evaluation determines which medication is most appropriate for your specific health profile, goals, and situation.
Gala offers telehealth evaluation and access to both semaglutide and tirzepatide — with licensed prescribers guiding medication selection based on your individual situation.
[Check if you qualify at Gala →]
This is a paid partnership. Gala is a licensed telehealth provider. Medication is only prescribed following a medical consultation and is not guaranteed.
The Bottom Line
Ozempic vs. Wegovy: Same drug (semaglutide), different doses and indications. Wegovy reaches higher doses approved for weight loss. Ozempic has better insurance coverage for people with diabetes.
Semaglutide vs. Tirzepatide: Different drugs, different mechanisms, clear efficacy winner. Tirzepatide produces approximately 6 percentage points more weight loss with fewer GI side effects. Semaglutide has stronger cardiovascular outcomes evidence.
Which is best overall?
On pure weight loss efficacy: Tirzepatide (Mounjaro/Zepbound)
On cardiovascular outcomes evidence: Semaglutide (Wegovy)
On cost and access: Similar through compounded telehealth options
For most people prioritizing maximum weight loss without specific cardiovascular disease considerations — tirzepatide is the current frontrunner. For people with established cardiovascular disease — semaglutide’s SELECT trial data provides compelling evidence for its use.
Both are dramatically more effective than any alternative non-surgical weight loss intervention available.
For the complete picture, see our guides to what are weight loss injections, who qualifies, and how much they cost.
Have you tried Ozempic, Wegovy, or Mounjaro — and which produced the best results for you? Share in the comments.
